A nationwide study of secondary progressive multiple sclerosis in the Danish population

Melinda Magyari, Tine Iskov Kopp, Stephan Bramow, Jette Lautrup Frederiksen Battisti, Claudia Hilt, Peter Vestergaard Rasmussen, Finn Sellebjerg

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Abstract

Objective: Using the nationwide Danish Multiple Sclerosis Registry we aimed to describe the population with seondary progressive multiple sclerosis(SPMS) disease course.Background: A population-based characterization of persons with SPMS has been lacking.Design/Methods: Beside the description of the clinician defined SPMS population, we aimed to define a population not coded as SPMS but fulfilling the following criteria at index date 19. June, 2019: Expanded Disability Status Scale (EDSS) score of 3.0textendash6.5 and 6 month confirmed EDSS worsening >=1 if EDSS lt;6 and >=0,5 if EDSS >=6,0 within 2 years before index date.Results: Of the 14619 persons with MS, 9043 (61.9 had RRMS, 2236 (15.3 SPMS, 1251 (8.5 PPMS and 2089 (14.3 were unclassified.The number of adults with SPMS was 2236 (66.4 . Of the population with relapsing MS 299 (71.5 persons fulfilled the criteria for worsening (worsening cohort).The median age of the SPMS population was 60.3 years (59.3 years for men and 60.8 years for women) and of the worsening cohort 48.2 years (47.6 years for men, 48.4 years for women). Median EDSS was 6.0 (SPMS) and 4.0 (worsening cohort).The median disease duration at SPMS conversion was 15.5 years, while 11.2 years in the worsening group. Relapses were recorded within 2 years in 5.1 0.4 70.0 with SPMS population did not received disease modifying therapy (DMT) at index date, 6.9 7.4 5.4 13.3 5.0 and 31.4 0.1 efficacy DMT.Conclusions: Treatment possibilities for progressive MS increase awareness on defining the accurate disease course.Disclosure: Dr. Magyari has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi, Merck, Roche, Biogen, Novartis, Abbvie, Almirall. Dr. Magyari has received research support from Novartis, Merck, Biogen.Dr. Iskov Kopp has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Bramow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Roche, Genzyme, and Merck. Dr. Bramow has received research support from Roche. Dr. Frederiksen Battisti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Sanofi--Genzyme, Teva, Novartis, Biogen Idec, Merck Serono, Sanofi-Aventis, Teva, Novartis, Almirall, Takeda. Dr. Pfleger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Biogen, Roche, Novartis, and Merck.. Dr. Pfleger has received personal compensation in an editorial capacity for Merck, Biogen. Dr. Vestergaard Rasmussen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Roche, Sanofi, Biogen, Novartis and TEVA,. Dr. Sellebjerg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Served on scientific advisory boards, been on the steering committees of clinical trials, served as a consultant, received support for congress participation, received speaker honoraria, or received research support for his laboratory from Biogen, Merck K. Dr. Sellebjerg has received research support from Served on scientific advisory boards, been on the steering committees of clinical trials, served as a consultant, received support for congress participation, received speaker honoraria, or received research support for his laboratory from Biogen, Merck K.
Original languageEnglish
JournalNeurology
Volume94
Issue number15, Supplement
Pages (from-to)2083
ISSN0028-3878
Publication statusPublished - 14 Apr 2020
EventAnnual Meeting of the American Academy of Neurology - Toronto, Canada
Duration: 25 Apr 20201 May 2020
https://www.aan.com/conferences-community/annual-meeting/

Conference

ConferenceAnnual Meeting of the American Academy of Neurology
CountryCanada
CityToronto
Period25/04/202001/05/2020
Internet address

Cite this